Gen Roche / BO45217
Trial Overview
Official Title
A Phase III Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib versus Sotorasib or Divarasib in patients with previously treated KRAS G12C-positive Advanced or Metastatic NSCLC.
Study Purpose
To evaluate the effectiveness of divarasib compared to currently approved Sotorasib or Adagrasib.
Diagnosis
Non-small cell lung cancer (NSCL) that is KRAS G12 C + If KRAS is unknown, study will test.Eligibility
Unresectable stage IIIC or IV that has progressed during or after at least one prior treatment regimen.
Intervention
Experimental arm: Divarasib
Control arm : Sotorasib or Adagrasib
For more information, go to the link below:
https://clinicaltrials.gov/study/NCT06497556?term=BO45217&rank=1
Key Participation Requirements
Trial Location(s)
Gender
Male/Female
Age
19 or older
Enrollment Status
Recruiting
Phase
Phase III
Methodist Health System Trial Code
BO45217